ECP Operator Day for NHSBT

19 November 2026

Windsor, UK

Download agenda PDF

Thursday, 19 November

13:00 – 13:05

Introduction

Claire Evans, Senior Territory Manager, Therakos

13:05 – 13:30

Medical device regulations — how do they affect you and why they are important

Fasi Payman, Medical advisor NEU, Therakos

13:30 – 14:00

ECP clinical indications — all you ever wanted to ask about GvHD, CTCLand SOT

Fasi Payman, Medical advisor NEU, Therakos

14:00 – 15:10

Kahoot interactive quiz — what we know: myth busting about ECP

Florianne Moorefield, Principal clinical specialist, Therakos

Jason Dimmock, Senior technical service specialist, Therakos

15:10 – 15:30

Coffee break

15:30 – 16:30

Delivering excellence in THERAKOS™ ECP

Florianne Moorefield, Principal clinical specialist, Therakos

Jason Dimmock, Senior technical service specialist, Therakos

16:30 – 17:15

Future research and developments in ECP

Dennis Briggs, Chief Innovation Officer, Therakos

17:15

Close

19:15

Meet for dinner

Friday, 20 November

08:45 – 09:00

Transport to office

09:15 – 10:00

Who should we treat with ECP in SOT?

Speaker TBC

10:00 – 10:45

SOT patient story – my ECP Journey

Patient TBC

Speaker TBC

10:45 – 11:00

Coffee break

11:00 – 12:00

Case scenario – interface management

Florianne Moorefield, Principal clinical specialist, Therakos

12:00 – 12:15

Survey and close

Claire Evans, Senior Territory Manager, Therakos

ECP: Extracorporeal Photopheresis, GvHD: Graft vs Host Disease, CTCL: Cutaneous T-cell Lymphoma, SOT: Solid Organ Transplantation

All speakers are subject to contract.

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

ECP Operator Day for NHSBT

Thursday, 19 November

Friday, 20 November

Brought to you by the Therakos Institute

Welcome to the Home of ECP

Thank you for visiting therakos.eu.

You are leaving the therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS